dc.contributor.author |
Ameratunga, Rohan |
|
dc.contributor.author |
Lehnert, Klaus |
|
dc.contributor.author |
Leung, Euphemia |
|
dc.contributor.author |
Comoletti, Davide |
|
dc.contributor.author |
Snell, Russell |
|
dc.contributor.author |
Woon, See-Tarn |
|
dc.contributor.author |
Abbott, William |
|
dc.contributor.author |
Mears, Emily |
|
dc.contributor.author |
Steele, Richard |
|
dc.contributor.author |
McKee, Jeff |
|
dc.contributor.author |
Muscroft-Taylor, Andrew |
|
dc.contributor.author |
Ameratunga, Shanthi |
|
dc.contributor.author |
Medlicott, Natalie |
|
dc.contributor.author |
Das, Shyamal |
|
dc.contributor.author |
Rolleston, William |
|
dc.contributor.author |
Quiñones-Mateu, Miguel |
|
dc.contributor.author |
Petousis-Harris, Helen |
|
dc.contributor.author |
Jordan, Anthony |
|
dc.coverage.spatial |
New Zealand |
|
dc.date.accessioned |
2021-08-13T01:27:05Z |
|
dc.date.available |
2021-08-13T01:27:05Z |
|
dc.date.issued |
2020-5-22 |
|
dc.identifier.citation |
New Zealand Medical Journal 133(1515):112-118 22 May 2020 |
|
dc.identifier.issn |
0028-8446 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/56002 |
|
dc.description.abstract |
COVID-19 is a new zoonotic disease caused by the SARS-CoV-2 virus. Since its emergence in Wuhan City, China, the virus has rapidly spread across the globe causing calamitous health, economic and societal consequences. It causes disproportionately severe disease in the elderly and those with co-morbidities, such as hypertension and diabetes. There is currently no proven treatment for COVID-19 and a safe and effective vaccine is at least a year away. The virus gains access to the respiratory epithelium through cell surface angiotensin converting enzyme 2 (ACE2). The receptor binding domain (RBD) of the virus is unlikely to mutate without loss of pathogenicity and thus represents an attractive target for antiviral treatment. Inhaled modified recombinant human ACE2, may bind SARS-CoV-2 and mitigate lung damage. This decoy strategy is unlikely to provoke an adverse immune response and may reduce morbidity and mortality in high-risk groups. |
|
dc.format.medium |
Electronic |
|
dc.language |
eng |
|
dc.publisher |
NEW ZEALAND MEDICAL ASSOC |
|
dc.relation.ispartofseries |
The New Zealand medical journal |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.rights.uri |
https://www.nzma.org.nz/pages/articles |
|
dc.subject |
Lung |
|
dc.subject |
Humans |
|
dc.subject |
Pneumonia, Viral |
|
dc.subject |
Coronavirus Infections |
|
dc.subject |
Peptidyl-Dipeptidase A |
|
dc.subject |
Recombinant Proteins |
|
dc.subject |
Administration, Inhalation |
|
dc.subject |
Protein Binding |
|
dc.subject |
Pandemics |
|
dc.subject |
Spike Glycoprotein, Coronavirus |
|
dc.subject |
Betacoronavirus |
|
dc.subject |
COVID-19 |
|
dc.subject |
Angiotensin-Converting Enzyme 2 |
|
dc.subject |
SARS-CoV-2 |
|
dc.subject |
Administration, Inhalation |
|
dc.subject |
Angiotensin-Converting Enzyme 2 |
|
dc.subject |
Betacoronavirus |
|
dc.subject |
COVID-19 |
|
dc.subject |
Coronavirus Infections |
|
dc.subject |
Humans |
|
dc.subject |
Lung |
|
dc.subject |
Pandemics |
|
dc.subject |
Peptidyl-Dipeptidase A |
|
dc.subject |
Pneumonia, Viral |
|
dc.subject |
Protein Binding |
|
dc.subject |
Recombinant Proteins |
|
dc.subject |
SARS-CoV-2 |
|
dc.subject |
Spike Glycoprotein, Coronavirus |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Medicine, General & Internal |
|
dc.subject |
General & Internal Medicine |
|
dc.subject |
CORONAVIRUS |
|
dc.subject |
SPIKE |
|
dc.subject |
1108 Medical Microbiology |
|
dc.subject |
Biomedical |
|
dc.subject |
Basic Science |
|
dc.subject |
Lung |
|
dc.subject |
Infectious Diseases |
|
dc.subject |
Immunization |
|
dc.subject |
Vaccine Related |
|
dc.subject |
Biodefense |
|
dc.subject |
Clinical Research |
|
dc.subject |
Clinical Trials and Supportive Activities |
|
dc.subject |
Prevention |
|
dc.subject |
Infection |
|
dc.subject |
5.1 Pharmaceuticals |
|
dc.subject |
11 Medical and Health Sciences |
|
dc.title |
Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infection. |
|
dc.type |
Journal Article |
|
pubs.issue |
1515 |
|
pubs.begin-page |
112 |
|
pubs.volume |
133 |
|
dc.date.updated |
2021-07-28T22:46:57Z |
|
dc.rights.holder |
Copyright: NZMA |
en |
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/32438383 |
|
pubs.end-page |
118 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Journal Article |
|
pubs.elements-id |
803025 |
|
dc.identifier.eissn |
1175-8716 |
|